EU/3/15/1434 - orphan designation for treatment of ovarian cancer
chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions (enadenotucirev)
OrphanHuman
Overview
On 12 February 2015, orphan designation (EU/3/15/1434) was granted by the European Commission to PsiOxus Therapeutics Ltd, United Kingdom, for chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions for the treatment of ovarian cancer.
This medicine is now known as enadenotucirev.
The sponsorship was transferred to Regulis Consulting Europe Limited, Ireland, in April 2019.
Please note that this product was withdrawn form the Union Register of orphan medicinal products in June 2021 on request of the Sponsor.
Ovarian cancer is cancer of the ovaries, the two organs in the female reproductive system that produce eggs. Most ovarian cancers occur in women over the age of 50 years. Due to the absence of symptoms in the early stages of the disease, the majority of patients are diagnosed when the cancer has spread to other parts of the body.
Ovarian cancer is a long-term debilitating and life-threatening disease that is associated with poor long-term survival.
At the time of designation, ovarian cancer affected less than 3 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 154,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).
At the time of designation, several medicines were authorised in the EU for the treatment of ovarian cancer. The choice of treatment depended mainly on how advanced the disease was. Treatments included surgery and chemotherapy (medicines to treat cancer).
The sponsor has provided sufficient information to show that this medicine might be of significant benefit for patients with ovarian cancer because early studies in experimental models showed that it might have improved effects in terms of slowing down the growth of the cancer, compared with currently authorised treatments. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
The medicine is made up of an 'oncolytic' virus that it is able to target, infect and destroy cancer cells, but does not infect normal cells. When inside a cancer cell, the virus is expected to take over the cell's replication apparatus and use it to make more copies of itself. This is expected to kill the cell, leaving the virus to spread to neighbouring cancer cells.
The effects of the medicine have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with ovarian cancer were ongoing.
At the time of submission, the medicine was not authorised anywhere in the EU for ovarian cancer or designated as an orphan medicinal product elsewhere for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 9 January 2015 recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions (enadenotucirev)
- Intended use
- Treatment of ovarian cancer
- Orphan designation status
- Withdrawn
- EU designation number
- EU/3/15/1434
- Date of designation
- Sponsor
Regulis Consulting Europe Limited
The Black Church
Saint Mary's Place
Dublin 7 DO7 P4AX
Ireland
Tel: +353 1 231 4691
E-mail: enquiries@regulis.com
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: